Medical technology company developing devices for cardiology, endoscopy, urology, neuromodulation, and other specialty procedures.
Profile & Fundamentals
Boston Scientific: Company identity, ownership, reported financial performance, balance sheets, and corporate actions.
Profile & Fundamentals
Boston Scientific Profile & Fundamentals
Examine company identity, ownership, reported performance, valuation, balance-sheet resilience, dividends, buybacks, and material corporate events.
Explore this pageJump to a Profile & Fundamentals section
Explore this research
Profile & Fundamentals contents
Jump directly to any section
Company and Market Context
Company Profile & Ownership
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Company profile record
Boston Scientific Corp
Common Stock · Health Care · Health Care Equipment
Company
- Company / asset
- Boston Scientific Corp
- Security type
- Common Stock
- Sector
- Health Care
- Industry
- Health Care Equipment
- HQ
- 🇺🇸 United States
- Head office
- 300 Boston Scientific Way, Marlborough, MA, United States, 01752-1234
Leadership & scale
- Chief executive
- Mr. Michael F. Mahoney
- CEO year born
- 1965
- Full-time employees
- 59K
- Fiscal year end
- December
- IPO date
- 1992-05-18
Fundamentals snapshot
- Market Cap
- USD 62.6B
- P/E
- 17.1x
- Revenue (Q2 26)
- USD 5.4B
- Profit (Q2 26)
- USD 907.0M
- Dividend Yield
- --
- Revenue (FY 25)
- USD 20.1B
- Shares in public float
- 1.4B
- Insider ownership
- 0.25%
Reporting & identifiers
- Symbol
- BSX.NYSE
- Listing
- 🇺🇸 United States | Dividend Tax: 30%
- Ticker Currency
- USD
- Income Statement Currency
- USD
- Balance Sheet Currency
- USD
- Cash Flow Currency
- USD
- EPS Currency
- USD
- Contract Type
- SPOT
- ISIN
- US1011371077
- Asset ID
- equity_55b13a19-f596-5d01-addd-94c29b3953c9
Ownership
Shares Outstanding
Latest: 1.5B | Max: 1.5B | Min: 1.4B
Latest reported ownership snapshot
As of Oct 1, 2026Float Shares
97.31%
1.4B latest reported shares
Insider Ownership
0.25%
Latest reported insider stake
Short Float
0.03%
Latest reported short interest / float
Top Holders
Source tablesView ownership tables
Shares Outstanding
Annual reported shares outstanding; up to 10 reporting dates.
Scroll the table to see every column.
| Reporting date | Shares outstanding |
|---|---|
| 2017-01-01 | 1,373,300,000 |
| 2018-01-01 | 1,406,200,000 |
| 2019-01-01 | 1,413,100,000 |
| 2020-01-01 | 1,440,600,000 |
| 2021-01-01 | 1,436,200,000 |
| 2022-01-01 | 1,442,400,000 |
| 2023-01-01 | 1,476,900,000 |
| 2024-01-01 | 1,490,200,000 |
| 2025-01-01 | 1,495,800,000 |
| 2026-01-01 | 1,484,900,000 |
Top Holders
Available reported ownership records.
Scroll the table to see every column.
| Holder | Shares | Ownership | Reported date |
|---|---|---|---|
| BlackRock Inc | 131,822,037 | 9.1% | 2026-03-31 |
| Vanguard Capital Management, LLC | 96,411,568 | 6.65% | 2026-03-31 |
| FMR Inc | 74,226,395 | 5.12% | 2026-03-31 |
| State Street Corp | 67,986,847 | 4.69% | 2026-03-31 |
| PRIMECAP Management Company | 50,520,914 | 3.49% | 2026-06-30 |
| Vanguard MStar Total Stk Mkt Idx Invest | 47,236,971 | 3.26% | 2026-08-31 |
| Vanguard 500 Index Investor | 39,489,384 | 2.72% | 2026-08-31 |
| JPMorgan Chase & Co | 33,350,157 | 2.3% | 2026-03-31 |
| Geode Capital Management, LLC | 33,285,757 | 2.3% | 2026-03-31 |
| Vanguard PRIMECAP Inv | 30,883,039 | 2.13% | 2026-06-30 |
| Vanguard Portfolio Management, LLC | 29,796,211 | 2.06% | 2026-03-31 |
| D. E. Shaw & Co LP | 25,457,409 | 1.76% | 2026-06-30 |
| Bank of America Corp | 22,756,646 | 1.57% | 2026-03-31 |
| Morgan Stanley - Brokerage Accounts | 22,266,664 | 1.54% | 2026-03-31 |
| NORGES BANK | 21,170,029 | 1.46% | 2026-06-30 |
Earnings, Profitability & Valuation
Earnings, Profitability & Valuation
Earnings & Revenue
Earnings and Revenue Trajectory
AI Review
Boston Scientific delivered strong revenue of $20.1 billion in fiscal 2025, surging nearly 20% year-over-year as its pioneering heart ablation systems gained rapid global adoption. However, growth slowed to 7.5% in the second quarter of 2026 as competing device makers launched rival systems and an August computer outage briefly disrupted factory shipments. This headline slowdown led management to trim full-year organic growth guidance to around 5% to 6%. Crucially, this deceleration represents a transition toward steady cash generation rather than corporate decay. Trailing twelve-month free cash flow reached a formidable $3.62 billion, proving that patient care generates dependable cash regardless of quarterly noise. Because scheduled cardiovascular procedures are deferred rather than canceled, cleared shipping backlogs will restore recognized earnings into 2027.
Boston Scientific delivered strong revenue of $20.1 billion in fiscal 2025, surging nearly 20% year-over-year as its pioneering heart ablation systems gained rapid global adoption. However, growth slowed to 7.5% in the second quarter of 2026 as competing device makers launched rival systems and an August computer outage briefly disrupted factory shipments. This headline slowdown led management to trim full-year organic growth guidance to around 5% to 6%. Crucially, this deceleration represents a transition toward steady cash generation rather than corporate decay. Trailing twelve-month free cash flow reached a formidable $3.62 billion, proving that patient care generates dependable cash regardless of quarterly noise. Because scheduled cardiovascular procedures are deferred rather than canceled, cleared shipping backlogs will restore recognized earnings into 2027.
Revenue, Net Income, and Free Cash Flow
Latest: USD 20.1B | Max: USD 20.1B | Min: USD -82.0M
Valuation
P/E Ratio (TTM)iPublished valuation snapshots use the earnings basis recorded with each observation. Source tables retain that basis.
Latest: 49x
Profitability & Margins
Margins and Operating Efficiency
AI Review
Profit margins widened significantly in fiscal 2025, with gross margins climbing to 69% and operating margins reaching nearly 20%. This profitability surge occurred because premium heart implants and specialty catheters carry strong pricing power and cost very little to produce once manufacturing reaches scale. High-margin procedure volume dropped directly to the bottom line. While competitor discounting in electrophysiology and temporary cyber recovery expenses will flatten near-term margins, long-term profitability remains well protected. An enterprise restructuring plan targeting $500 million in annual overhead savings by 2029 will counterbalance pricing pressures. As higher-margin vascular products integrate into global sales channels, operating margins should sustainably stabilize above 22%. over time.
Profit margins widened significantly in fiscal 2025, with gross margins climbing to 69% and operating margins reaching nearly 20%. This profitability surge occurred because premium heart implants and specialty catheters carry strong pricing power and cost very little to produce once manufacturing reaches scale. High-margin procedure volume dropped directly to the bottom line. While competitor discounting in electrophysiology and temporary cyber recovery expenses will flatten near-term margins, long-term profitability remains well protected. An enterprise restructuring plan targeting $500 million in annual overhead savings by 2029 will counterbalance pricing pressures. As higher-margin vascular products integrate into global sales channels, operating margins should sustainably stabilize above 22%. over time.
Profitability Margins
Latest: 69.0% | Max: 69.0% | Min: -0.8%
Latest Profitability Ratios as of 2025-12-31
Gross Margin
69.0%
Gross profit / revenue
Operating Margin
19.8%
Operating income / revenue
Net Margin
14.4%
Net income / revenue
FCF Margin
18.2%
Free cash flow / revenue
Source tablesView earnings, profitability & valuation tables
Revenue, Net Income, and Free Cash Flow
Annual reported results, using the source statement's recorded USD conversion. Up to 10 reporting periods; missing values are not estimated.
Scroll the table to see every column.
| Period end | Revenue (USD) | Net income (USD) | Free cash flow (USD) |
|---|---|---|---|
| 2016-12-31 | 8,386,000,000 | 347,000,000 | 596,000,000 |
| 2017-12-31 | 9,048,000,000 | 104,000,000 | 1,107,000,000 |
| 2018-12-31 | 9,823,000,000 | 1,671,000,000 | -6,000,000 |
| 2019-12-31 | 10,735,000,000 | 4,700,000,000 | 1,375,000,000 |
| 2020-12-31 | 9,913,000,000 | -82,000,000 | 1,132,000,000 |
| 2021-12-31 | 11,888,000,000 | 1,040,000,000 | 1,316,000,000 |
| 2022-12-31 | 12,682,000,000 | 698,000,000 | 914,000,000 |
| 2023-12-31 | 14,240,000,000 | 1,593,000,000 | 1,703,000,000 |
| 2024-12-31 | 16,747,000,000 | 1,854,000,000 | 2,645,000,000 |
| 2025-12-31 | 20,074,000,000 | 2,886,000,000 | 3,658,000,000 |
Published P/E Ratio
Published valuation snapshots retain each observation's earnings basis.
Scroll the table to see every column.
| Period end | P/E (times earnings) | Earnings basis |
|---|---|---|
| 2025-12-31 | 49.35 | Trailing four quarters |
| 2024-12-31 | 71.83 | Trailing four quarters |
| 2023-12-31 | 53.63 | Trailing four quarters |
| 2022-12-31 | 95.62 | Annual net income |
| 2021-12-31 | 58.66 | Annual net income |
Profitability Margins
Matching annual reporting dates. Values are percentages.
Scroll the table to see every column.
| Period end | Gross margin (%) | Operating margin (%) | Net margin (%) | Free cash flow margin (%) |
|---|---|---|---|---|
| 2016-12-31 | 63.71 | 14.74 | 4.14 | 7.11 |
| 2017-12-31 | 64.89 | 16.85 | 1.15 | 12.23 |
| 2018-12-31 | 65.94 | 17.68 | 17.01 | -0.06 |
| 2019-12-31 | 64.08 | 15.95 | 43.78 | 12.81 |
| 2020-12-31 | 56.25 | 6.06 | -0.83 | 11.42 |
| 2021-12-31 | 62.76 | 16.17 | 8.75 | 11.07 |
| 2022-12-31 | 60.83 | 14.38 | 5.5 | 7.21 |
| 2023-12-31 | 62.02 | 15.32 | 11.19 | 11.96 |
| 2024-12-31 | 61.31 | 15.73 | 11.07 | 15.79 |
| 2025-12-31 | 69.01 | 19.78 | 14.38 | 18.22 |
Public data excerpt created by iPulse AI and published by Future Edge Group FZE. Source: eodhd. Snapshot retrieved 2026-09-29.
Use is subject to the iPulse AI Terms of Service and applicable source rights. Missing inputs are not estimated. Full access includes the remaining records, research and interactive tools.
Complete Research Workspace
Unlock the complete Profile & Fundamentals
Sign in to verify your access, or upgrade to the Base plan to open the complete profile & fundamentals and available source data.